Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab Induction and Maintenance in Japanese Patients with Crohn's Disease
NCT02038920Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2014
- Primary completion
- Jan 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of vedolizumab in Crohn's disease, sponsored by Takeda. Started Jan 2014; status: completed.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02038920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02038920.